This case illustrates the heterogeneity of tumor molecular biology in the stage IV setting, and the potential of 68Ga-EMP-100 PET/CT for pre-therapeutic and non-invasive assessment of whole-body c-MET expression in NSCLC patients prior to c-MET targeting tyrosine kinase inhibitors such as cabozantinib [2, 5]. The gene discussed is MET; the disease is neoplasm.